DIRS.INFO The most relevant business & tech news

A 0.25 mg injection pen of Novo Nordisk's weight-loss drug Wegovy is shown in this photo illustration in Oslo, Norway, September 1, 2023. REUTERS/Victoria Klesty/Illustration/File Photo Acquire Licensing RightsLONDON/NEW YORK, Oct 23 (Reuters) - The growth in demand for appetite suppressing anti-obesity drugs like Novo Nordisk's (NOVOb.CO) Wegovy presents opportunities for food manufacturers and the market's initially downbeat reaction may be overdone, investors say. Still, the stock market impact left some food manufacturers "trembling," said John Plassard, senior investment specialist at Nestle investor Mirabaud Group. The uptake in appetite suppressing drugs seems to be a U.S.-led dynamic, said My Nguyen, research analyst at Legal & General Investment Management America. "Elsewhere, trends such as wealthier, more mobile middle classes in emerging countries can support shifts towards snacking and convenience foods."

Persons: Victoria Klesty, Richard Saldanha, Wegovy, Kiran Aziz, Mark Schneider, John Plassard, Brian Frank, Frank, Nguyen, Richa Naidu, Matt Scuffham, Kirsten Donovan Organizations: REUTERS, Walmart, Nestle, Aviva, Novo Nordisk, EY, Industry, Health Sciences, Wellness, Mirabaud, Tyson Foods, Arcos Dorados, Legal, General Investment Management America, Germany's, Investments, Unilever, Coca Cola, Thomson Locations: Oslo, Norway, Victoria, United States, Denmark, Germany, Arda, Ural, U.S

☆ These 7 'left for dead' value stocks will outperform while the tech trade unwinds in an imminent recession, according to a fund manager who beat 99% of his peers last year
▼ + stars: | 2023-06-15 | by ( James Faris | ) www.businessinsider.com time to read: +4 min

Fund manager Brian Frank explained why he's bearish on tech stocks and the economy. Here are seven stocks he's bullish on now as value makes a comeback in a recession. Value is the best bet in a weak economyConsidering how growth stocks have retaken the throne from their value counterparts this year, Frank said he's pleased with how his Frank Value Fund (FRNKX) has fared. The mid-cap fund, which Frank has single-handedly managed for nearly 19 years, has outperformed 74% of its peers in 2023, according to Morningstar. "You would think, given the economic data, defensives would trade at a premium to the market," Frank said.

Persons: Brian Frank, Frank, It's, —, he's, Morningstar, we're, that's, he's bullish Organizations: Frank Value Fund, Home, Walmart

Search resuls for: "Frank Value Fund"

2 mentions found